To review the scientific data on the role of sexually transmitted diseases (STDs) in sexual transmission of HIV infection and discuss the implications of these findings for HIV and STD prevention policy and practice. Methods: Articles were selected from a review of Medline, accessed with the OVID search engine. The search covered articles from January 1987 to September 1998 and yielded 2101 articles. Methods used to uncover articles which might have been missed included searching for related articles by author, and combing literature reviews. In addition, all abstracts under the category "sexually transmitted diseases" from the XI and XII International Conferences on AIDS (Vancouver 1996 and Geneva 1998) and other relevant scientific meetings were reviewed. Efforts were made to locate journal articles which resulted from the research reported in the identified abstracts. All original journal articles and abstracts which met one of the following criteria were included: (1) studies of the biological plausibility or mechanism of facilitation of HIV infectiousness or susceptibility by STDs, (2) prospective cohort studies (longitudinal or nested case-control) which estimate the risk of HIV infection associated with specific STDs or STD syndromes, or (3) intervention studies which quantitate the eVect which STD treatment can have on HIV incidence. Results: Strong evidence indicates that both ulcerative and non-ulcerative STDs promote HIV transmission by augmenting HIV infectiousness and HIV susceptibility via a variety of biological mechanisms. These eVects are reflected in the risk estimates found in numerous prospective studies from four continents which range from 2.0 to 23.5, with most clustering between 2 and 5. The relative importance of ulcerative and non-ulcerative STDs appears to be complex. Owing to the greater frequency of non-ulcerative STDs in many populations, these infections may be responsible for more HIV transmission than genital ulcers. However, the limited reciprocal impact of HIV infection on non-ulcerative STDs and the evidence that non-ulcerative STDs may increase risk primarily for the receptive partner (rather than bidirectionally) may modulate the impact of these diseases. The results of two community level randomised, controlled intervention trials conducted in Africa suggest that timely provision of STD services can substantially reduce HIV incidence, but raise additional questions about the optimal way to target and implement these services to achieve the greatest eVect on HIV transmission. Conclusions: Available data leave little doubt that other STDs facilitate HIV transmission through direct, biological mechanisms and that early STD treatment should be part of a high quality, comprehensive HIV prevention strategy. Policy makers, HIV prevention programme managers, and providers should focus initial implementation eVorts on three key areas: (i) improving access to and quality of STD clinical services; (ii) promoting early and eVective STD related healthcare behaviours; and (iii) establishing surveillance systems to monitor STD and HIV trends and their interrelations. (Sex Transm Inf 1999;75:3-17) 
Introduction
As the interrelation between human immunodeficiency virus (HIV) infection and other sexually transmitted diseases (STDs) has become increasingly well understood, the need to translate these scientific findings into sustainable prevention programmes and policy has become increasingly urgent. In fact, recent evidence that, at a community level, STD treatment can substantially decrease HIV incidence has compelling implications for both STD and HIV prevention, and argues for improved coordination between these often separate eVorts.
Recent developments have added complexity and urgency to this topic. For example, technological innovations have made widespread STD screening and treatment easier and more eVective, both in industrialised and developing countries. In the United States and several other countries, the epidemiology of HIV itself is changing, with heterosexual transmission accounting for larger proportions of new infections and aVecting increasing numbers of women. Furthermore, the advent of new HIV therapies, which promise to transform HIV infection into a "chronic disease," may have already begun to change perceptions about the importance of maintaining safe sexual behaviours. 1 Finally, new health services research has documented the inadequacy of existing STD prevention capacity in the United States, as well as most of the developing world. [2] [3] [4] Clearly, additional approaches to preventing HIV infection are now feasible and necessary.
With these issues in mind, we will review the scientific foundation for our understanding of the role STDs play in facilitating sexual transmission of HIV, focusing on data from studies published since 1990. We will then discuss the implications of these findings for HIV and STD prevention policy and practice by highlighting initial steps in activities such as community based behavioural intervention, surveillance, and clinical services that would help build truly synergistic HIV and STD prevention programmes.
Evidence defining the contribution of other STDs to sexual transmission of HIV infection
author, and combing literature reviews. In addition, all abstracts under the category "sexually transmitted diseases" from the XI and XII International Conferences on AIDS (Vancouver 1996 and Geneva 1998) and other relevant scientific meetings were reviewed. EVorts were made to locate journal articles which resulted from the research reported in the abstracts we identified. All original journal articles and abstracts which met one of the following three criteria were included in the review: (1) studies of the biological plausibility or mechanism of facilitation of HIV infectiousness or susceptibility by STDs, (2) prospective cohort studies (longitudinal or nested casecontrol) which estimate the risk of HIV infection associated with specific STDs or STD syndromes, or (3) intervention studies which quantitate the eVect which STD treatment can have on HIV incidence. The remaining studies were excluded. These were primarily those that did not directly address relations between HIV and other STDs, and those that employed case-control or cross sectional study designs. BIOLOGICAL 
PLAUSIBILITY
Promotion of HIV transmission by STDs, both ulcerative and non-ulcerative, may occur by a variety of biological mechanisms, which are likely to aVect both HIV infectiousness and susceptibility. Firstly, other STDs facilitate HIV shedding in the genital tract, which probably promotes HIV infectiousness. This has been demonstrated by testing genital secretions for the presence of HIV and, more recently, for the HIV concentration. Secondly, STDs also appear to increase susceptibility to HIV, by recruiting HIV susceptible inflammatory cells to the genital tract and by disrupting mucosal barriers to infection. We will discuss each of these eVects separately.
The relation between STDs and genital HIV shedding is potentially confounded by the level of immunosuppression, since advancing immunosuppression may promote STD acquisition or persistence, 5 as well as HIV shedding. 7 Evidence that the role of STDs is independent of level of immunosuppression comes from studies that adjust for level of immunosuppression in the analysis or demonstrate reduced HIV shedding after STD treatment. Therefore, these considerations are important in assessing the quality and generalisability of the results of this group of studies.
EVect of genital ulcers on HIV infectiousness and susceptibility
Genital ulcers bleed frequently during sexual intercourse, resulting in potential increases in HIV infectiousness (table 1) . In HIV infected individuals, HIV has been detected frequently in genital ulcer exudates. 8 9 Among 609 HIV-1 positive female sex workers in Cote d'Ivoire, detection of HIV-1 by cervicovaginal lavage was also markedly increased among women with cervicovaginal ulcers compared with those without lesions (55.8% versus 21.5%). This eVect persisted after adjustment for level of immunosuppression (adjusted odds ratio (OR), 3.9, 95% confidence interval (CI) 2.1-7.4). Among the limited number of women with ulcers who returned after approximately 1 week, successful treatment reduced HIV-1 detection to levels similar to those among women who did not have ulcers at enrolment. 10 Among 86 HIV-1 infected men presenting to a Malawi STD clinic with urethritis, the presence of genital ulcer disease (GUD) increased HIV concentration in seminal plasma, particularly among those with non-gonococcal urethritis (NGU) (median copy number × 10 4 19.5 v 0.4 for NGU plus GUD v NGU alone). 11 However, in contrast with the findings in Cote d'Ivoire, GUD was not an independent predictor of seminal HIV shedding, but instead appeared to increase viral load in semen by increasing blood plasma HIV concentrations, possibly because GUD patients had more advanced HIV disease or systemic immune activation. 11 In another recent study, detection of replication competent HIV from herpetic genital ulcers was common, and was correlated with recovery of HSV-2 by culture from the lesions. 12 These findings are consistent with recent evidence that HIV transcription and plasma viral load may increase during acute episodes of HSV-1 infections. 13 Conversely, among HIV seronegative individuals, genital ulcers may increase susceptibility to HIV by disrupting mucosal integrity, and by increasing the presence and activation of HIV susceptible cells in the genital tract. 14 15 Haemophilus ducreyi, for example, evokes a cell mediated immune response which attracts HIV susceptible cells to the ulcer surface. 16 In fact, H ducreyi may contain specific T cell stimulating antigens, 17 which may further predispose T cells to infection by HIV. In addition, with viral STDs such as herpes, there may be interactions between viruses in the genital tract which promote the establishment of HIV infection. For example, in tissues co-infected with HSV-1, HIV-1 virions appear able to infect keratinocytes that lack CD4 receptors and, therefore, are not usually vulnerable to HIV infection. 18 In gaining access to cells, HIV may also take advantage of changes in cellular chemokine receptors that result from infection with other viruses, as shown recently in studies of cytomegalovirus. 19 
EVect of non-ulcerative STDs on HIV infectiousness and susceptibility
Non-ulcerative STDs such as gonorrhoea and chlamydia also increase HIV shedding in the genital tract (table 2) , probably by recruiting HIV infected inflammatory cells as part of the normal host response. Among HIV positive men in Nairobi, prevalence of detectable HIV in genital secretions increased in the presence of gonorrhoea (adjusted OR 3.2, 95% CI 1.6-6.4) and, with successful therapy, was halved from 44% to 21%, a level similar to the 19% found among men without urethritis at enrolment. 20 In a US study, seminal leucocytosis also predicted HIV detection in semen (adjusted OR 7.0, 95% CI 1.3-39.3). 21 In addition, several studies in men have documented an association between non-ulcerative STDs and increased concentration of HIV shedding by showing that HIV nucleic acid copy number in semen is elevated in the presence of non-ulcerative STDs. [22] [23] [24] In the largest of these studies, involving 135 HIV-1 positive men in Malawi, median HIV-1 concentrations in seminal plasma were eight and 10 times higher among men with urethritis and gonorrhoea, respectively, than among men without urethritis. 23 Two weeks after appropriate treatment, HIV-1 concentrations among urethritis patients were reduced by two thirds to levels that were not significantly diVerent from those among controls without urethritis (p=0.9).
Among women, data linking non-ulcerative STDs and HIV shedding are more preliminary, but growing rapidly. Investigators in Mombasa, HIVquasi-species in ulcers later appeared in serum, suggesting replication competence.
FSW=female sex workers; GUD=genital ulcer disease; PCR=polymerase chain reaction; NGU=non-gonococcal urethritis; GC=gonorrhoea; OR=odds ratio; CI=confidence interval.
From epidemiological synergy to public health policy and practice
Kenya found that HIV shedding was associated with gonorrhoea (univariate OR 3.1 (95% CI 1.1-9.8), and Gram stain evidence of cervicitis or vaginitis, but not with chlamydial or trichomonal infection. 25 In the Cote d'Ivoire study mentioned above, after adjustment for level of immunosuppression in multivariate analysis, HIV was at least twice as frequently detected among women with gonorrhoea or chlamydia as among women without these STDs. The results of successful treatment of the 83 women with gonorrhoea in this study were reminiscent of the findings among men in Nairobi co-infected with HIV and gonorrhoea: the prevalence of HIV shedding fell from 42% to 24% (p<0.01). HIV shedding also decreased from 50% to 38% among the 16 women successfully treated for chlamydia, but the decrease did not achieve statistical significance. 10 Although two studies of Nairobi prostitutes showed no statistically significant associations between specific STDs and HIV shedding, these studies did suggest a strong correlation between HIV detection and cervical mucopus (adjusted OR 6.2, 95% CI 0.9-41.4) 26 or cervical inflammation by Gram stain or Papanicolaou smear (adjusted OR 8.7, 95% CI 2.0-37.2). 27 The authors speculate that extremely frequent gonococcal infection and treatment with antibiotics among their subjects may have hampered their ability to detect true associations. 27 Among pregnant women, genital HIV shedding has an additional dimension, the potential for increased transmission from mother to child during delivery. Pregnancy itself appears to promote HIV shedding. 26 27 In a recent study of pregnant women, HIV detection in genital secretions was also associated with cervical mucopus, but not with gonococcal or chlamydial cervicitis. 28 In HIV negative individuals, non-ulcerative STDs appear to increase susceptibility to HIV 29 In addition, in vitro data suggest that Chlamydia trachomatis not only recruits polymorphonuclear leucocytes, but may also interact with these cells to increase HIV replication. 30 
SEROCONVERSION STUDIES
Recent prospective studies of new HIV infections in the presence of STDs have made the leap from biological plausibility to observed phenomenon. In the majority of these studies, to document the temporal sequence of STD acquisition and HIV seroconversion, groups of initially HIV negative people were followed with repeated physical examinations and HIV tests, although some studies relied on self reports of STDs. Importantly, a number of these studies included enough seroconversions to control for sexual behaviour as a potential confounder of the relation between STDs and HIV infection. We will discuss only prospective studies, and will emphasise those that used objective STD detection methods and adjusted for sexual behaviour. For summaries of casecontrol and cross sectional studies, we refer the reader to several recent reviews. 5 31 32 Genital ulcer disease of mixed or unspecified aetiology and HIV transmission Nine prospective studies address genital ulcer disease (GUD) of mixed or unspecified aetiology (table 3 ). In this group of studies, the authors presented measures of risk of HIV seroconversion associated with genital ulcers, regardless of aetiology. Overall, six of these nine studies used an objective STD detection method to document active infection (that is, clinical or laboratory examination) and adjusted for sexual behaviour. All six showed a strong eVect of GUD on HIV acquisition, with adjusted odds ratios or risk ratios between 2.2 and 11.3.
Five of these studies address female to male HIV transmission. Cameron and colleagues 33 studied 293 men who had acquired an STD from female sex workers in Nairobi, Kenya. The ulcers they acquired were primarily (89%) chancroid. Overall, 24 men seroconverted to HIV, and those with ulcers were almost five times as likely to acquire HIV as those without GUD, even after adjustment for sexual behaviour. A second study, conducted among factory workers in Zimbabwe, also reported a more than threefold increase in risk of HIV seroconversion among those with self reported genital ulcers, despite the study's limitation of failing to use clinical or laboratory methods to detect GUD.
33A Two studies conducted in Thailand examined cohorts of male conscripts during their 2 years of military service. One of these, a cohort study of 1036 men of whom 14 became HIV infected, found that men who self reported GUD during the study were more than 13 times as likely to HIV seroconvert as those who did not report acquiring a genital ulcer. 34 Although H ducreyi, HSV-2 and syphilis serologies were obtained at enrolment, these markers of earlier infection were not associated with increased risk of incident HIV infection. The second study used a nested case-control design with careful adjustment for sexual behaviour and documented a two to threefold increased risk of HIV seroconversion among men with serological evidence of H ducreyi or HSV-2 during the study period. 35 Finally, in New York City, Telzak and colleagues 36 studied 758 heterosexual men attending an STD clinic, of whom 14 HIV seroconverted. Chancroid was not as common in this study as in that by Cameron et al, but still accounted for 40% of GUD cases. People with chancroid were about three times as likely to HIV seroconvert as those who were not infected. Significant associations were not detected for syphilis or herpes, but misclassification bias may have occurred because almost 40% of chancroid cases were diagnosed on clinical criteria, and HSV cultures were not obtained.
Male to female transmission of HIV was studied among 124 female sex workers in Nairobi. After adjustment for sexual behaviour, those who developed GUD were three times as likely to HIV seroconvert as those who remained free of STDs (adjusted OR 3.3, 95% CI 1.2-10.1). 37 Three articles examined HIV seroconversion for men and women in the same analysis. In a study of 256 serodiscordant European couples, HIV seroincidence was five times as high among non-index partners with self reported genital ulcers as among those without STDs. 38 This result was statistically significant, although cases of GUD were too few to control for sexual behaviour. In a Baltimore STD clinic, among a retrospectively defined cohort of 147 clinic returnees tested at least twice for HIV, after adjustment for sexual behaviour, those with GUD were 11 times more likely to seroconvert than those without infection. 39 Finally, among members of a large cohort of patients at two STD clinics in Pune, India, patients who had GUD on examination at their pre-seroconversion visit were more than four times as likely to seroconvert as those who did not. Furthermore, those who had GUD both before and after HIV seroconversion were more than eight times as likely to acquire HIV infection. It could not be determined whether the GUD present in the second visit (after seroconversion) was acquired at the same time as HIV, or at some other time, before or after seroconversion. 40 
Genital herpes and HIV transmission
Eight studies specifically address genital herpes as a factor in HIV seroconversion (table 4) . Prospective data linking genital herpes with increased risk of HIV transmission are more equivocal than those for genital ulcers, particularly of bacterial aetiologies. This may be due, in part, to the fact that HSV-2 infection is a chronic disease manifested by recurrent anogenital ulcers, the frequency and severity of which decline in most patients over time. Therefore, while studies that use HSV-2 serology oVer the advantage of a sensitive and specific ascertainment of HSV infection status, this measure may correlate poorly with recent genital ulceration which is the risk factor of importance. This means that studies of seroprevalent herpes, especially those in which Three studies address heterosexual transmission, in this case, female to male. In the two studies mentioned above that were conducted among Thai military conscripts, HSV-2 infection was detected serologically. After adjustment for sexual behaviour, in the nested case-control study, HSV-2 antibodies were three times as common among HIV seroconverters at the study visit before that at which HIV seroconversion was documented as among persistently HIV negative men at the analogous visit (adjusted OR 3.1, 95% CI 1.2-7.9). 35 However, in the cohort study in which HSV-2 antibodies were obtained only at enrolment, the fourfold increase in risk of HIV seroconversion that was observed in bivariate analysis fell to a twofold relative risk that failed to achieve statistical significance after adjustment for sexual behaviour (adjusted risk ratio (RR) 2.0, 95% CI 0.6-6.1). 34 In the third study, there was no association of genital herpes with HIV acquisition, but ascertainment of HSV infection (by clinical examination and Tzanck preparation) was probably so insensitive that many HSV infections were missed. 36 Three additional analyses which employed the more sensitive measure, HSV-2 antibody, were all conducted in homosexual men. Holmberg et al 41 studied HSV-2 antibody among 47 HIV seroconverting homosexual men and 57 matched controls in San Francisco, USA, and found that HSV-2 seropositive men were significantly more likely to acquire HIV than those without HSV-2 antibody. HSV-2 seroconversion resulted in an even greater increase in risk of HIV seroconversion. These associations persisted after potential confounding by sexual behaviour was addressed through log linear analysis. A similar nested case-control study of homosexual men in Amsterdam also documented increased risk of HIV acquisition associated with HSV-2 seropositivity. 42 Only one of the three analyses, a nested case-control study of homosexual men in San Francisco matched on prior level of receptive anal intercourse, 43 failed to show an association between genital herpes and increased risk of HIV acquisition. Interestingly, of the two other studies which were conducted among homosexual men and relied exclusively upon self reported herpes as the outcome measure, one 44 found a strong association, and the other 45 was unable to document any relation.
Syphilis and HIV transmission
Nine studies examined the role of syphilis in HIV acquisition (table 5). The majority are limited either by small numbers of syphilis cases or by reliance on self reported history to ascertain a syphilis diagnosis. However, four of the six studies with 10 or more syphilis cases revealed a significant association between syphilis and increased risk of HIV transmission on multivariate analysis, with risk estimates that range from 2.3 to 8.6. 44 46-48 The other two studies, one conducted using clinical and laboratory indicators of syphilis among heterosexual men in New York 36 and the other conducted using self reported syphilis among homosexual men in Vancouver, 45 reported univariate risk estimates of 3.4 and 3.8, respectively, but these associations did not remain significant after adjustment for sexual behaviour.
Of the six studies with suYcient numbers of syphilis cases to permit multivariate analysis, two were conducted among heterosexuals, 36 46 three among homosexual men, 44 45 47 and one did not restrict the analysis with respect to route of sexual transmission. 48 In Miami, investigators found that among a retrospective cohort of 106 women who were HIV negative during antenatal testing on average 3.8 years earlier, those who became HIV infected were more than eight times as likely to have serological evidence of syphilis documented in their medical records since their pregnancies than women who remained free of HIV infection (adjusted OR 8.6, 95% CI 1.0-84). 46 In contrast, the New York study of heterosexual male STD clinic patients mentioned above did not demonstrate a significant association between syphilis and HIV acquisition on multivariate analysis. 36 This may have reflected, in part, the fact that syphilis patients were compared with non-GUD STD clinic patients rather than with men who did not receive an STD diagnosis. All three studies that were conducted among homosexual men relied on self reported history of syphilis, which is neither sensitive nor specific for detection of the disease. Nevertheless, two of these studies reported unadjusted odds ratios of 2.3 and 3.5 which remained significant in multivariate analysis. 44 47 Strong evidence that syphilis facilitates HIV transmission is also provided by the remaining study of over 5100 patients who were tested twice for HIV at four Miami STD clinics. 48 Patients who were diagnosed with syphilis between the two HIV tests were almost three times as likely to HIV seroconvert as those who were diagnosed with syphilis before the first HIV test. These patients, in turn, were almost one and a half times as likely to seroconvert as those in whom syphilis was never diagnosed. The first of these analyses included only patients who had had syphilis at some point, and who shared behavioural risk factors for syphilis. Assuming that these risk factors remained stable over time, the ratio of HIV incidences in the two groups represents a measure of the additional risk of acquiring HIV incurred by having syphilis during an HIV exposure. Uniquely, this study also adjusted for the higher prevalence in Miami of HIV infection among syphilis patients than among patients with other STDs. This factor contributes importantly to the true population attrib-utable risk of syphilis, but it may upwardly bias the estimate of the facilitating eVect of syphilis on HIV transmission.
Non-ulcerative STDs and HIV transmission
Non-ulcerative STDs also appear to play a role in facilitating HIV transmission, with risk estimates from 13 prospective studies that are largely similar to those for ulcerative STDs (table 6) . However, the relative importance of ulcerative and non-ulcerative STDs in HIV transmission is probably complex. If the eVect of non-ulcerative STDs on HIV acquisition is, indeed, in the range indicated by these studies, the ultimate impact of non-ulcerative STDs on the HIV epidemic could potentially be much greater than that of GUD because nonulcerative STDs are far more common than genital ulcers in most populations. On the other hand, the impact of non-ulcerative STDs may be more limited than that of GUD for two reasons. Firstly, HIV infection does not alter the natural history or response to therapy of non-ulcerative STDs to the same extent that it does for GUD. 5 Thus, the "epidemiological synergy" that fuels the mutually reinforcing spiral of infection observed with ulcerative STDs and HIV infection is far more modest or absent with non-ulcerative STDs. Secondly, the available data suggest (tables 3-6) and it is biologically plausible that, while genital ulcers increase HIV risk bidirectionally for both receptive and insertive sex partners (for example, among heterosexuals for both female to male and male to female transmission), nonulcerative STDs may increase risk primarily for the receptive partner. Almost all of the studies specifically supporting a role for gonorrhoea, chlamydial infection, or trichomoniasis document an increased risk of male to female HIV transmission (table 6). The two exceptions are a study of STD clinic patients in which the increased HIV risk was carried by those individuals who experienced male to female HIV transmission, 39 and a study of homosexual men in which rectal gonorrhoea, but not urethral or pharyngeal infection, was associated with HIV acquisition in multivariate analysis. 45 Mathematical models may be helpful in understanding the dynamic interplay of these factors in a range of settings.
Gonorrhoea and HIV transmission
Eleven of the 13 prospective studies of non-ulcerative STDs specifically address gonococcal infection. Of these, nine showed a statistically significant association of gonorrhoea with HIV seroconversion, although in two of the studies 47 5.1 with the exception of one study which reported an adjusted odds ratio of 23.5.
46
The majority of the studies of gonorrhoea examine male to female HIV transmission. Three relatively large studies of family planning clinic clients in Dar es Salaam, antenatal clinic patients in Blantyre, and female sex workers in Kinshasa, [51] [52] [53] documented adjusted risk estimates of 4.2, 4.3, and 4.8, respectively, while a smaller study of women identified through prenatal care in Florida found an adjusted odds ratio of 23.5 with a wide confidence interval. 46 Another smaller study of female STD clinic patients in Nairobi found an unadjusted relative risk of 5.0. 50 However, three additional studies of male to female gonorrhoea transmission among female sex workers in Chiang Rai, Cameroon, and Nairobi failed to show a significant association with HIV acquisition in multivariate analysis. 37 49 54 The smaller sample sizes with more limited numbers of HIV seroconversions or relatively low incidences of gonorrhoea in two of these studies 37 54 may, in part, explain these divergent results.
One study addresses gonorrhoea and HIV transmission among both men and women. In this study, conducted among STD clinic attenders in Baltimore, 39 gonorrhoea was associated with a fivefold increase in risk of HIV seroconversion. As mentioned above, unpublished subgroup analyses suggested that the increased risk here, too, was carried primarily among those individuals experiencing male to female transmission (unadjusted OR 7.2 (CI 0.8-64) for male to female transmission, and Urethritis/cervicitis on exam ± GS (171 urethritis and 35 cervicitis cases).
Adj OR 3.0 (1.4-6.5) for urethritis/cervicitis before seroconversion; 3.7 (1.1-13.2) for recurrent infection.
Potential bias due to 26% response rate; no laboratory confirmation of aetiology.
SC=seroconverters; GUD=genital ulcer disease; FSW=female sex workers; FP=family planning; CT=Chlamydia trachomatis; EIA=enzyme immunoassay; GC=gonorrhoea; BV=bacterial vaginosis; PID=pelvic inflammatory disease; GS=Gram stain; RR=risk ratio; OR=odds ratio; NS=not significant.
2.0 (CI, 0.8-4.9) for female to male transmission (William Kassler, personal communication)). Unfortunately, there are few prospective data on male to male transmission of gonorrhoea. The two published studies conducted among homosexual men both relied upon self reports of gonorrhoea and found that gonococcal infection was associated with HIV seroconversion in univariate analysis. 45 47 On multivariate analysis, one study found that rectal gonorrhoea increased risk of HIV acquisition threefold, while urethral and pharyngeal infection were no longer associated with increased risk. 45 The other study, which did not include analyses by anatomical site of gonococcal infection, no longer revealed a significant association. 47 
Other non-ulcerative STDs and HIV transmission
Other non-ulcerative STDs such as chlamydial infection and trichomoniasis are also linked to HIV seroconversion, although fewer studies have addressed these diseases, perhaps because accurate detection of these organisms is more technically diYcult than is detection of gonorrhoea (table 6). In the two studies from Africa in which chlamydia was diagnosed in women by enzyme immunoassay (EIA) 51 and by culture, 37 adjusted odds ratios were 3.6 and 2.7, respectively. A third study conducted among women in Miami using EIA reported and adjusted odds ratio of 10.7 with wide confidence intervals. 46 Trichomonal infection in women was found to be associated with HIV acquisition (with borderline statistical significance) in Kinshasa, 51 but not in Blantyre or Baltimore. 39 53 One group at a Nairobi STD clinic found that clinically diagnosed pelvic inflammatory disease (PID) was strongly associated with HIV acquisition, with unadjusted odds ratio of 6.3. 50 Although PID itself would be unlikely to increase HIV transmission risk, it may be assumed that PID in this study is a proxy for previous infection with gonorrhoea, chlamydia, or other pathogens. Finally, two prospective studies considered the role of urethritis or cervicitis in HIV transmission. In a study of both men and women at an STD clinic in India, Mehendale and colleagues found an association between HIV acquisition and urethritis or cervicitis, with an adjusted odds ratio of 3.0 (95% CI 1.4-6.5). 40 Self reported urethritis was also strongly associated with HIV acquisition among male Thai military conscripts (adjusted RR 6.0, 95% CI 1.8-20.9). 34 Recent evidence suggests that bacterial vaginosis, which is not an STD, but which causes abnormal vaginal discharge, may also increase risk of HIV infection, although the biological mechanism responsible for this finding is not yet clear. 52 55 
POPULATION ATTRIBUTABLE RISK OF STDS FOR HIV TRANSMISSION AND MATHEMATICAL MODELS
A number of the HIV seroconversion studies discussed above provide suYcient information to calculate, for a given study, the population attributable risk (PAR) of various sexually transmitted diseases for HIV acquisition (table  7) . The PAR is a measure of the proportion of cases of disease in a population that could, theoretically, be averted by removing a given exposure if an intervention were able to achieve complete coverage and optimal eVectiveness. It takes into account not only the magnitude of the risk associated with the exposure, but also the prevalence of the exposure in the population of interest. 56 VittinghoV and Padian 57 discuss the strengths and limitations of the PAR as applied to STDs. It should be noted that in the specific case of studies of HIV seroconversion related to other STDs, the PAR may substantially underestimate potentially avertable cases because it reflects only the eVect of STDs on HIV susceptibility and does not capture the eVect on HIV infectiousness. PARs for GUD were generally higher than those for non-ulcerative STDs. It is interesting to note that the PARs of GUD in studies conducted in the developing world were higher (44%-69%) than in those conducted in the United States (7%-18%), largely reflecting the lower prevalence of these diseases in the United States than in developing countries. This observation underscores the fact that a given PAR applies specifically to the population studied at a given phase of an epidemic, and may not easily translate to other populations. In the United States, for example, the STD attributable HIV transmission risk could feasibly be increasing, as heterosexual modes of transmission assume a larger role in HIV epidemiology.
Mathematical models of the impact of other STDs on HIV transmission suggest that the eVect of these diseases may be much greater than is suggested by studies using standard epidemiological analytical approaches to estimate eVects at a given time. Dynamic models may more accurately reflect the explosive way in which the eVect of STDs is multiplied through ongoing HIV transmission. [58] [59] [60] [61] Some models suggest that STD incidence and preva- lence may be critical to sustaining heterosexual transmission of HIV infection. Modelling also suggests that the eVectiveness and cost eVectiveness of STD treatment in HIV prevention may be greater during earlier stages of an HIV epidemic, before HIV infection becomes widely distributed [62] [63] [64] [65] and the relative importance of incurable viral STDs, like herpes, begins to increase. Finally, mathematical models highlight the importance of providing STD treatment to those who are most likely to transmit infection to others in order to maximise the population level impact and cost eVectiveness of STD control interventions. 66 
INTERVENTION TRIALS
Although very valuable, the observational studies discussed above are inherently subject to a number of potential limitations, and they cannot directly measure the eVect of STD control on HIV incidence in the larger population. 5 58 67-70 Quasi-experimental intervention projects conducted among female sex workers (FSWs) in Zaire, Kenya, and Bolivia have shown that routine STD clinical services and condom promotion may be associated with dramatic reductions in HIV incidence or prevention of epidemic increases in HIV infection in high risk populations. [71] [72] [73] In the Zairian study, for example, HIV incidence rose from 2.7 per 100 women years among FSWs who attended more than 90% of their monthly clinic visits to 7.1, 20.3, and 44.1 per 100 women years among FSWs who attended 76-90%, 50-75%, and less than 50% of their scheduled visits, respectively. 71 However, without randomised, controlled designs, these studies, too, have limited ability to demonstrate causal relations and estimate the magnitude of the intervention eVect.
Two community level randomised, controlled intervention trials have been conducted in Africa, the first in the Mwanza region of Tanzania, and the second in the Rakai district of Uganda. Both of these trials attempted to quantitate the eVect of STD treatment on HIV incidence by randomising entire communities to receive either some form of augmented STD treatment or the local standard of STD care. A third community level randomised, controlled trial is currently ongoing in the Masaka district of Uganda. Its three arms compare the eVect on HIV incidence of (i) behavioural intervention to promote safer sex, and (ii) improved STD management plus the behavioural intervention, with a comparison group receiving community development activities.
Mwanza trial: improved clinic based treatment of symptomatic STDs to reduce HIV incidence
Investigators in Mwanza, Tanzania, provided continuous access to improved treatment for symptomatic STDs through existing primary healthcare clinics in six rural communities. 74 The intervention included training of staV from health centres and dispensaries in STD diagnosis and treatment using syndromic algorithms, assuring a regular supply of drugs, implementing routine supervisory visits to health facilities, and establishing an STD reference clinic and laboratory. In addition, health educators in the intervention areas visited villages to provide information on STDs, focusing on the availability of eVective treatment and encouraging prompt treatment of symptomatic STDs. For 24 months the six matched, comparison communities received STD clinical services that were unchanged from those that had existed previously, at which time the intervention was also implemented in the comparison communities.
After 24 months, this intervention resulted in a 38% reduction in HIV incidence in the intervention communities compared with the control communities. 74 In each of the six communities that received this relatively modest intervention, HIV incidence was substantially lower than in the corresponding matched comparison community (range 12%-65%). Importantly, the greatest impact of the intervention was in women aged 15-24 years, and men aged 25-34, groups in which the HIV incidence was highest in the comparison communities. Significant reductions were documented in the prevalence of serologically diagnosed syphilis (RPR >1:8; adjusted RR 0.71, 95% CI 0.54-0.93) and borderline significant reductions were observed in the prevalence of new cases of syphilis (RPR >1:8; adjusted RR 0.62, 95% CI 0.38-1.02) and of symptomatic urethritis in the previous year (adjusted RR 0.51, 95% CI 0.25-1.03). 75 These results were not associated with changes in sexual behaviour or condom use that might confound the association between improved STD treatment and HIV transmission.
Economic analysis of the STD treatment intervention in Mwanza showed that it was cost eVective in preventing HIV infection at US$218 per HIV infection averted and $10 per disability adjusted life year (DALY) saved. 76 These estimates compare favourably with other eVective and widely implemented public health interventions such as childhood immunisation (estimated cost eVectiveness $12-17 per DALY saved). 76 Rakai trial: intermittent home based mass treatment of STDs to reduce HIV incidence In Rakai, Uganda, investigators tested another approach to STD treatment for HIV prevention. 77 In the intervention communities, which were grouped into five clusters of four to seven villages reflecting social and sexual networks, directly observed mass treatment for curable STDs was provided irrespective of symptom status at 10 month intervals in subjects' homes using single dose antibiotics (oral azithromycin, ciprofloxacin, and metronidazole and intramuscular benzathine penicillin for serological evidence of syphilis). In the five control community clusters, home based mass treatment was provided in a single blinded fashion using an antihelminth (mebendazole), iron folate, and low dose multivitamins. Symptomatic subjects who were encountered in control communities during mass treatment rounds were referred for STD care to the project's mobile clinics which were available only during these periods. All study subjects were oVered HIV prevention education and serological counselling, condoms, and free general health care at the project's mobile clinics.
After three mass treatment rounds that spanned 20 months and included two follow up intervals, HIV incidence was similar in the intervention and control communities overall (adjusted rate ratio 0.97, 95% CI 0.81-1. 16 ) and in each of the randomised pairs. 77 By the third round, significant reductions were observed in the prevalence of serologically diagnosed syphilis (adjusted prevalence ratio 0.80, 95% CI 0.71-0.89) and trichomoniasis (adjusted prevalence ratio 0.59, 95% CI 0.38-0.91), and in the incidence of trichomoniasis (adjusted RR 0.52, 95% CI 0.35-0.79), but not of syphilis. Borderline significant reductions in bacterial vaginosis (BV) prevalence also occurred (adjusted prevalence ratio 0.87, 95% CI 0.74-1.02).
Mwanza and Rakai results: consistent or contradictory?
Why did STD treatment dramatically reduce HIV incidence in Mwanza, but not in Rakai? Although superficially the results of these two landmark, community level, randomised, controlled trials may appear contradictory, in fact, the two studies tested diVerent STD treatment interventions using diVerent measurement approaches in populations with diVerent HIV and STD epidemiology. The findings are, not surprisingly, diVerent, but consistent and complementary.
Among the multiple factors that may have contributed to the divergent results of the two trials at least four explanations probably combined to produce the dramatic reduction in HIV incidence in Mwanza and the equally stunning absence of eVect on HIV incidence in Rakai.
Firstly, in light of the frequency with which most individuals have sex, it is logical that continuous access to improved STD treatment services would be more eVective than intermittent mass treatment administered as infrequently as every 10 months. For example, in Rakai, individuals who became infected within days after a mass treatment round had few STD treatment options for the next 10 months other than the inadequate clinic care that had existed before the trial.
Secondly, symptomatic STDs may be more important than asymptomatic infections in facilitating HIV transmission, while asymptomatic STDs may be more central to ongoing spread of STDs and development of sequelae. Biologically, this is because symptomatic STDs are more likely than asymptomatic cases to be associated with fulminant inflammatory responses or larger ulcers, factors that facilitate HIV transmission. Asymptomatic STDs, on the other hand, are more likely to persist untreated and, as a result, spread to others or progress to complications in the original patient. Symptomatic STDs also often reflect recently acquired or incident infections and, therefore, recent risky sexual behaviours. Thus, focusing on symptomatic STDs may be a very eVective way to target STD treatment interventions.
Thirdly, as discussed above, STDs may play a greater role in HIV transmission in earlier than in later phases of an HIV epidemic. As HIV epidemics mature and infection becomes widely disseminated in the population, exposure of the limited number of individuals who remain biologically and behaviourally susceptible becomes increasingly independent of cofactors such as STDs. Furthermore, the relative contribution of curable STDs may decline in late HIV epidemics as viral STDs like genital herpes become common. The Rakai district was experiencing a far more advanced HIV epidemic during that study than the Mwanza region was during its trial, with baseline HIV prevalence of 16% and 4%, respectively. 74 77 Finally, local STD incidence, prevalence, and aetiological spectrum are critical determinants of the impact of any STD treatment intervention on HIV transmission. The STD detection methods used in the Rakai study were much more sophisticated and extensive than those used in the Mwanza trial, making direct comparisons diYcult. However, the available data suggest that while syphilis prevalence rates were probably comparable in the two study populations, gonorrhoea and chlamydia prevalence may have been slightly higher in Mwanza and the proportion of genital ulcers due to HSV-2 was probably substantially higher in Rakai.
Implications for policy and practice
The extensive observational and growing intervention trial data leave little doubt that other STDs facilitate HIV transmission through direct, biological mechanisms. 78 79 The question is no longer whether STD detection and treatment should be an essential component of HIV prevention programmes, but rather how this component should be implemented to have maximal impact on HIV incidence in specific populations. 80 The intervention studies currently suggest that intermittent mass treatment, alone, delivered to the general population is not an eVective approach to STD control for HIV prevention, particularly in a late HIV epidemic with relatively low rates of curable STDs. However, targeted mass treatment (for example, among high frequency transmitters or others with high STD incidence or prevalence) at relatively short intervals deserves additional examination in combination with establishment of high quality, continuous STD treatment services to achieve a rapid, initial reduction in STD rates as a "lead in" to more comprehensive, sustained STD control measures.
Policy makers, HIV prevention programme managers, and providers must focus initial implementation eVorts on three key areas: (i) improving access to and quality of STD clinical services; (ii) promoting early and eVective STD related healthcare behaviours; and (iii) establishing surveillance systems to monitor STD and HIV trends and their interrelation. Guide-lines addressing these areas have recently been published in the United States, 80 and UNAIDS and the World Health Organisation are planning to develop analogous guidelines to assist developing country programmes.
Initial steps to ensure access to and quality of STD clinical services should, at a minimum, focus on public and private settings that serve individuals who are HIV infected or at high risk for HIV acquisition. These steps should include assessing and ensuring timely access to quality STD diagnostic and treatment services for symptomatic people seeking care; establishing or expanding STD screening in medical and non-medical settings for asymptomatic people who are at high risk for HIV infection and other STDs; and providing relevant training to programme managers and clinicians. 80 In industrialised countries, STD screening strategies in venues such as substance abuse treatment centres, correctional institutions, HIV counselling and testing sites, schools, and community centres in high morbidity areas may capitalise on the advent of urine based nucleic acid amplification tests and single dose antibiotic regimens. In developing countries, where resource constraints frequently preclude widespread use of aetiological tests, primary emphasis should be placed on assuring access to high quality STD clinical services for symptomatic people in medical and non-medical settings. This will require widespread training of providers in the use of algorithms for syndromic STD management, which perform well in the diagnosis of genital ulcers and urethritis. 81 It will also necessitate re-evaluation of vaginal discharge algorithms which have limited sensitivity and specificity in detection of cervicitis, 81 as well as a greater commitment to assure consistent availability of eVective STD drugs at local levels. Providing HIV counselling, testing, and referral to individuals diagnosed with other STDs is clearly an important complementary strategy.
Promotion of early and eVective STD related healthcare behaviours must begin to complement the important risk reduction messages that, in many parts of the world, currently focus almost exclusively on sexual behaviours. The critical new messages for individuals at risk for HIV infection and other STDs include (i) other STDs facilitate the spread of HIV infection, thus STD detection and treatment is an HIV prevention strategy; (ii) recognising and acting on STD symptoms are important; and, in settings where screening is feasible, (iii) most STDs occur without symptoms, so regular screening is vital. People must also be provided with specific information about sources of STD services. A complementary set of messages must be developed for providers. 81 An essential condition for eVective and cost eVective implementation of STD treatment as an HIV prevention strategy is establishment at the local level of basic STD and HIV surveillance systems with linkages that permit policy makers, programme managers, and providers to determine, in their community, the extent of overlap between STD and HIV infected populations and, therefore, the relative importance locally of STD treatment in the mix of HIV prevention strategies. These systems should also provide information on the aetiological spectrum of STDs. These data must be analysed, disseminated, and used on a routine, timely basis to guide decision making as both HIV and STD epidemics evolve.
In summary, STD control is a central priority in its own right. Almost two decades into the most devastating pandemic of our times, we have strong evidence that early detection and treatment of other STDs can be a powerful addition to the HIV prevention arsenal in populations with substantial burdens of curable STDs, particularly in early HIV epidemics. While we must continue to refine our understanding of how best to implement STD control to prevent HIV transmission in specific populations, initial steps to assess potential impact and, where epidemiologically appropriate, incorporate STD treatment as part of a comprehensive HIV prevention strategy are clear. We must not hesitate any longer to take those steps. 
